ArticleFrontiers in immunology2017
Good Manufacturing Practice-Compliant Production and Lot-Release of
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04691232 (Phase I, Open-label, Fast-track Dose-escalation Clinical Trial Exploring the Safety and the Tolerability of Autologous ex Vivo Expanded Regulatory T Cells in Adults With Ulcerative Colitis), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I, Open-label, Fast-track Dose-escalation Clinical Trial Exploring the Safety and the Tolerability of Autologous ex Vivo Expanded Regulatory T Cells in Adults With Ulcerative Colitis
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Regulatory T Cells and Nanomaterials: Dual Perspectives in Therapeutics and Immunomodulation.Small science · 2026Review
- Lactic acid improves Treg manufacturing andMolecular therapy. Methods & clinical development · 2025Article
- Clinical grade expansion protocol for the manufacture of thymus-derived Treg cells for clinical application.Journal of translational medicine · 2025Article
- Clinical Manufacturing of Regulatory T Cell Products For Adoptive Cell Therapy and Strategies to Improve Therapeutic Efficacy.Organogenesis · 2023Review
- Flagellin-specific human CAR Tregs for immune regulation in IBD.Journal of autoimmunity · 2023Article
- Increased Motility and Suppression of Ex Vivo-Expanded Regulatory T Cells Designed for Adoptive Transfer Therapy in Ulcerative Colitis.Cellular and molecular gastroenterology and hepatology · 2023Article
- Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential.Cellular and molecular life sciences : CMLS · 2022Review
- Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product.Journal of translational medicine · 2022Article
- Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective.Frontiers in cell and developmental biology · 2022Review
- Article
- Nanoparticles Engineered as Artificial Antigen-Presenting Cells Induce Human CD4Frontiers in immunology · 2021Article
- Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs andFrontiers in immunology · 2021Article
- Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells.Nature communications · 2020Article
- Resolution of ulcerative colitis.Seminars in immunopathology · 2019Review
- Stability and inhibitory function of Treg cells under inflammatory conditionsExperimental and therapeutic medicine · 2019Article
- Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System.Frontiers in immunology · 2019Article
- Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells.Hepatology international · 2018Review
- Clinical Applications of Regulatory T cells in Adoptive Cell Therapies.Cell & gene therapy insights · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the exploration of regulatory T cell (Treg)-based cellular therapy has become an attractive strategy to ameliorate inflammation and autoimmunity in various clinical settings. The main obstacle to the clinical application of Treg in human is their low number circulating in peripheral blood. Therefore,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.